<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRPO</journal-id><journal-title-group><journal-title>Asian Case Reports in Oncology</journal-title></journal-title-group><issn pub-type="epub">2169-8821</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRPO.2020.94004</article-id><article-id pub-id-type="publisher-id">ACRPO-38318</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRPO20200400000_47221964.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  TACE联合索拉非尼治疗原发性肝癌的研究进展
   Research Progress of TACE Combined with Sorafenib in the Treatment of HCC
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姚</surname><given-names>欣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>建军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院肿瘤介入科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>10</month><year>2020</year></pub-date><volume>09</volume><issue>04</issue><fpage>17</fpage><lpage>21</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   原发性肝癌(Hepatocellular carcinoma, HCC)起病隐匿，虽然手术治疗是首选，但患者因出现临床症状而就医时大多已进入中晚期，选择单纯的手术治疗不能达到预期的目的。针对这部分患者，肝动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)已成为首选。然而，采用此治疗方式，虽然能一定程度上缓解病情，但治疗效果有限。多项研究表明采用TACE联合索拉非尼的治疗方法，可以使中晚期原发性肝癌患者获益颇多，本文参考相关资料，探讨TACE联合索拉非尼治疗原发性肝癌的相关研究进展。 Hepatocellular carcinoma (HCC) has an insidious onset. Although surgical treatment is the first choice, most of the patients have entered the middle and advanced stages when they seek medical attention due to clinical symptoms, and surgical treatment alone cannot achieve the expected goals. For these patients, transcatheter arterial chemoembolization (TACE) has become the first choice. Although this treatment method can relieve the condition to a certain extent, the treatment effect is limited. A number of studies have shown that the use of TACE combined with sorafenib can benefit patients with advanced Hepatocellular carcinoma. This article refers to related materials to discuss the research progress of TACE combined with sorafenib in the treatment of Hepatocellular carcinoma. 
  
 
</p></abstract><kwd-group><kwd>原发性肝癌，HCC，肝动脉化疗栓塞术，TACE，索拉非尼,  Hepatocellular Carcinoma</kwd><kwd> HCC</kwd><kwd> Hepatic Artery Chemoembolization</kwd><kwd> TACE</kwd><kwd> Sorafenib</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>原发性肝癌(Hepatocellular carcinoma, HCC)起病隐匿，虽然手术治疗是首选，但患者因出现临床症状而就医时大多已进入中晚期，选择单纯的手术治疗不能达到预期的目的。针对这部分患者，肝动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)已成为首选。然而，采用此治疗方式，虽然能一定程度上缓解病情，但治疗效果有限。多项研究表明采用TACE联合索拉非尼的治疗方法，可以使中晚期原发性肝癌患者获益颇多，本文参考相关资料，探讨TACE联合索拉非尼治疗原发性肝癌的相关研究进展。</p></sec><sec id="s2"><title>关键词</title><p>原发性肝癌，HCC，肝动脉化疗栓塞术，TACE，索拉非尼</p></sec><sec id="s3"><title>Research Progress of TACE Combined with Sorafenib in the Treatment of HCC<sup> </sup></title><p>Xin Yao, Jianjun Yang<sup>*</sup></p><p>Department of Interventional Oncology, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/1-2530106x5_hanspub.png" /></p><p>Received: Oct. 7<sup>th</sup>, 2020; accepted: Oct. 21<sup>st</sup>, 2020; published: Oct. 28<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/1-2530106x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Hepatocellular carcinoma (HCC) has an insidious onset. Although surgical treatment is the first choice, most of the patients have entered the middle and advanced stages when they seek medical attention due to clinical symptoms, and surgical treatment alone cannot achieve the expected goals. For these patients, transcatheter arterial chemoembolization (TACE) has become the first choice. Although this treatment method can relieve the condition to a certain extent, the treatment effect is limited. A number of studies have shown that the use of TACE combined with sorafenib can benefit patients with advanced Hepatocellular carcinoma. This article refers to related materials to discuss the research progress of TACE combined with sorafenib in the treatment of Hepatocellular carcinoma.</p><p>Keywords:Hepatocellular Carcinoma, HCC, Hepatic Artery Chemoembolization, TACE, Sorafenib</p><disp-formula id="hanspub.38318-formula5"><graphic xlink:href="//html.hanspub.org/file/1-2530106x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2530106x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2530106x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>原发性肝癌具有很高的恶性程度，一旦发病就会迅速恶化，并且复发、转移的风险也很高 [<xref ref-type="bibr" rid="hanspub.38318-ref1">1</xref>]。最新资料表明，原发性肝癌是目前我国发病第4位及死亡第3位的常见恶性肿瘤，严重威胁着人们的生命健康 [<xref ref-type="bibr" rid="hanspub.38318-ref2">2</xref>]。巴塞罗那临床肝癌分期系统(BCLC)是最常用的HCC管理指南 [<xref ref-type="bibr" rid="hanspub.38318-ref3">3</xref>]。张磊等 [<xref ref-type="bibr" rid="hanspub.38318-ref4">4</xref>] 总共将198项观察性研究纳入荟萃分析，结果表明手术切除加经导管动脉化疗栓塞和手术切除加索拉非尼的应用是巴塞罗那临床肝癌分期系统B和C期的最佳策略。虽然手术切除病灶是原发性肝癌的首选治疗方法，但大多数患者在发现时已经错过了手术治疗的最佳时机。此时，非手术治疗肝癌显得尤为重要。目前，TACE是公认的肝癌非手术治疗中最常用的方法之一 [<xref ref-type="bibr" rid="hanspub.38318-ref5">5</xref>]。它具有创伤小、恢复快、住院时间短、对患者的工作和生活影响较小等一系列优点，是中晚期肝癌患者不错的选择。此外，靶向药物索拉非尼的问世，又为肝癌的治疗提供了新的思路和方法。而二者的联合治疗或可使中晚期患者看到希望的曙光。本文参考相关资料，探讨TACE联合索拉非尼治疗原发性肝癌的相关研究进展。</p></sec><sec id="s6"><title>2. 肝动脉化疗栓塞治疗</title><p>对于无法切除的肝细胞癌(HCC)同时无大血管浸润和肝外转移的患者，推荐的初始治疗选择是经动脉化疗栓塞(TACE) [<xref ref-type="bibr" rid="hanspub.38318-ref6">6</xref>]。肝动脉化疗栓塞治疗是将化疗药物与超液化碘化油混合液通过微创介入的方式灌注于肿瘤的供血动脉中，借此杀灭肿瘤细胞，有效抑制肿瘤的生长。在巴塞罗那临床肝癌(BCLC) B期，肝动脉化疗栓塞(TACE)是肝细胞癌(HCC)患者的推荐治疗方法 [<xref ref-type="bibr" rid="hanspub.38318-ref7">7</xref>]。自2004年以来，已经使用了两种TACE技术：常规TACE (cTACE)和带有药物洗脱珠的TACE (DEB-TACE)。事实证明，cTACE首先可治疗中期HCC患者。它结合了使用基于Lipiodol的乳剂和栓塞剂的经导管化学疗法，以实现强大的细胞毒性和局部缺血作用。为了缓慢释放化学治疗剂并增加缺血强度和持续时间，开发了药物洗脱珠(DEB)。最近的进展使得TACE治疗既可以用于早期阶段的患者(即那些在3 cm以下具有单个结节或最多3个结节的患者)，也可以用于某些晚期阶段的患者 [<xref ref-type="bibr" rid="hanspub.38318-ref8">8</xref>]。在一项比较常规TACE方案的随机对照试验的荟萃分析中，研究显示TACE可将中位生存期提高16到20个月。改善该患者组结局的各种策略已成为许多正在进行的临床研究的主题。栓塞药物洗脱珠(DEB)的引入已证明可显着改善TACE的药代动力学特性，提供了常规方案无法提供的一致性和重复性水平，同时显著减少了全身性药物暴露 [<xref ref-type="bibr" rid="hanspub.38318-ref9">9</xref>]。</p><p>王瑞航等 [<xref ref-type="bibr" rid="hanspub.38318-ref10">10</xref>] 讨论TACE对原发性肝癌患者近期疗效及Child-Pugh分级的影响。纳入95例患者，分为对照组(n = 46)与观察组(n = 49)。对照组行射频消融治疗，观察组行TACE治疗，观察组总有效率高于对照组(观察组为81.63%，对照组为60.87%)，Child-Pugh分级优于对照组(观察组79.59%为A级，20.41%为B级；对照组63.04%为A级，36.96%为B级)，差异有统计学意义(P &lt; 0.05)；两组不良反应总发生率比较(观察组为6.12%，对照组为8.70%)，差异无统计学意义(P &gt; 0.05)。结论为原发性肝癌患者应用TACE治疗近期疗效较佳，可有效改善Child-Pugh分级，且安全性高，不良反应少。为明确不同化疗药物是否具有不同的疗效，赵梦蝶等 [<xref ref-type="bibr" rid="hanspub.38318-ref11">11</xref>] 通过荟萃分析确定含铂与蒽环类药物的TACE对肝细胞癌(HCC)患者的临床疗效，其中涉及1405例患者，在分别比较随机对照试验和观察性研究后，得出的结论是：铂和蒽环类药物在治疗反应，不良事件和总生存率方面没有显著差异。</p></sec><sec id="s7"><title>3. 索拉非尼治疗</title><p>分子靶向药物索拉非尼是晚期原发性肝癌(HCC)患者的标准一线治疗药物。它通过靶向RAF/MEK/ERK途径和受体酪氨酸激酶来抑制肿瘤生长和血管生成 [<xref ref-type="bibr" rid="hanspub.38318-ref12">12</xref>]。SHARP和Oriental研究的两项多中心III期随机双盲临床试验的结果表明索拉非尼能够延长晚期原发性肝癌患者的总生存期，但对于我国晚期肝癌患者来说，其预后不容乐观。</p><p>Leal CRG等 [<xref ref-type="bibr" rid="hanspub.38318-ref13">13</xref>] 评估了一大批Child-Pugh B(CP-B)HCC患者与Child-Pugh A(CP-A)HCC患者相比的总生存期(OS)和对索拉非尼的耐受性。纳入130例晚期HCC患者，患者分为CP-A (n = 65)或CP-B (n = 65)。所有130名患者的平均OS为10个月。CP-A患者的中位生存期显着长于CP-B患者：12个月vs 6个月。在我们的CP-B患者组中发现的OS为6.5个月，这比迄今为止进行的大多数研究中发现的OS高。经索拉非尼治疗的CP-B HCC患者的这一现实队列具有比文献所述更高的生存率，并具有令人满意的安全性。尽管CP-B患者中严重不良事件(AE)的患病率很高，但该组中的治疗中断较少，这表明Child-Pugh B患者可以耐受治疗，并可能受益于索拉非尼。另一项研究为讨论年龄因素是否与索拉非尼的毒性反应相关，Ziogas DC等 [<xref ref-type="bibr" rid="hanspub.38318-ref14">14</xref>] 纳入190名患者(157名男性)的数据，将患者分为两组：(A) 75岁以下和(B) 75岁以上。我们的终点是由于疾病进展或毒性导致的总生存期(OS)和治疗失败时间(TTF)。中位年龄为66岁(26~87岁) (A = 151和B = 39)。两组之间的OS和TTF均无显著差异[7.1 (5.5~8.7)个月与10.4 (6.5~14.3)个月，P = 0.360和4.2 (2.3~6.2)与5.6 (3.1~8.1)个月，P = 0.369]。A组和B组在所有级别上的毒性发生率和剂量降低均相当。结果显示：老年晚期肝癌患者接受索拉非尼治疗后，其临床结果与年轻患者具有相同的毒性反应率。在一些研究中，索拉非尼与肝动脉灌注化疗(HAIC)相比对晚期肝细胞癌(HCC)的临床益处和安全性不一致。庄伯文等 [<xref ref-type="bibr" rid="hanspub.38318-ref15">15</xref>] 评估索拉非尼与HAIC对晚期HCC患者的有效性和安全性。包括14项对1779例患者的回顾性研究(索拉非尼 = 773，HAIC = 1006)。根据实体瘤反应评估标准，HAIC在客观缓解率(优势比0.13；95% CI，0.07~0.24)和疾病控制率(优势比0.48；95% CI，0.26~0.87)方面均取得了良好的效果。总体生存的总危险比为0.60 (95% CI, 0.39~0.91)，无进展生存的总危险比为0.69 (95% CI, 0.51~0.95)，进一步表明HAIC优于索拉非尼，具有更好的肿瘤反应，更长的总生存期和无进展生存期，是一种安全有效的替代方案。</p></sec><sec id="s8"><title>4. 肝动脉化疗栓塞联合索拉非尼治疗</title><p>肝动脉化疗栓塞联合分子靶向药物索拉非尼可以在晚期原发性肝癌的治疗中发挥积极的作用。近年来，关于TACE联合索拉非尼的研究层出不穷，或可使患者获益。</p><p>张秀萍等 [<xref ref-type="bibr" rid="hanspub.38318-ref16">16</xref>] 关于经肝动脉化疗栓塞加索拉非尼(TACE-S)在具有门静脉肿瘤血栓(PVTT)的肝细胞癌(HCC)中的益处的荟萃分析，涉及1091名患者(TACE-S = 356, TACE = 735)。联合治疗组总生存期(OS)的范围为7到13个月，仅TACE组为4到6.1个月；联合治疗组的疾病进展时间(TTP)中位数为6.2个月，而单纯TACE治疗组为2.4个月。结果表明，与TACE相比，TACE-S可以改善PVTT的HCC患者的总生存期和进展时间。同样，贾媛等 [<xref ref-type="bibr" rid="hanspub.38318-ref17">17</xref>] 的研究也得出了类似的结论。共有498例患者入选该研究，其中69例接受TACE联合索拉非尼治疗的患者和429例单独接受TACE治疗的患者。使用1:2倾向评分匹配138纳入平衡良好的患者。比较两组的总生存期(OS)。与单独使用TACE相比，TACE联合索拉非尼改善了患者的OS (13.0 vs 6.0个月，P &lt; 0.001)。倾向评分匹配后，联合治疗和TACE的中位OS分别为13.0和7.0个月(P = 0.001)。与单独的TACE治疗相比，TACE联合索拉非尼可以改善HBV背景HCC合并PVTT患者的OS。黄永辉等 [<xref ref-type="bibr" rid="hanspub.38318-ref18">18</xref>] 评估TACE + 索拉非尼与TACE单药治疗BCLC B期HCC的疗效。涉及2008年1月至2014年1月间接受TACE (n = 144)或TACE + 索拉非尼(n = 46)的BCLC B期肝癌患者。TACE + 索拉非尼组的总生存期(OS)为18.0个月，而TACE组为10.0个月(P = 0.002)。显然，TACE + 索拉非尼联合使用可能改善BCLC B期肝癌患者的OS。Kok VC等 [<xref ref-type="bibr" rid="hanspub.38318-ref19">19</xref>] 对接受索拉非尼治疗aHCC (Child-Pugh A)并伴大血管侵犯或淋巴结转移的患者(n = 3674；中位年龄，60；83%男性)进行队列研究，将患者分为索拉非尼-TACE组(n = 426)或索拉非尼–单独组(n = 1686)。在索拉非尼-TACE组和索拉非尼单独组的中位随访期221天和133天，分别发生了164例(39%)和916例(54%)死亡。相应的中位总生存期(OS)分别为381天和204天(危险比，HR：0.74；95%置信区间，CI，0.63~0.88；P = 0.021)。索拉非尼-TACE组的一年和六个月的OS分别为53.5%和80.3%，而单索拉非尼组的OS为32.4%和54.4%。两组的主要并发症相当。在索拉非尼中添加TACE可改善生存率，并使死亡率降低26%。支持了符合条件的Child-Pugh A aHCC患者的这种联合治疗策略。林莉等 [<xref ref-type="bibr" rid="hanspub.38318-ref7">7</xref>] 的荟萃分析着重于确定TACE与索拉非尼的组合疗效。包括二十七项研究，十三项非比较性研究报告了OS的中位数(从18.5到20.4个月)，TTP的中值(从7.0到13.9个月)和DCR (疾病控制率) (从18.4%到95%)。十四项比较研究提供了中位OS (从7.0到29.7个月不等)和中位TTP (从2.6到10.2个月不等)。五项比较研究提供了疾病控制率(DCR)的数据，范围从32%到97.2%。与单独使用TACE相比，联合治疗显著改善了TTP (HR = 0.66, 95% CI 0.50~0.81, P = 0.002)，联合治疗组DCR显著升高(OR = 2.93, 95% CI 1.59~5.41, P = 0.005)。就延长TTP和DCR而言，联合治疗可能使无法切除的HCC患者受益。范峰等 [<xref ref-type="bibr" rid="hanspub.38318-ref20">20</xref>] 的研究结果表明，TACE (羟基喜树碱 + 吡柔比星) + 索拉非尼组和TACE (羟基喜树碱 + 表柔比星) + 索拉非尼组有明显的疗效差异。总之，对于晚期肝癌患者，在TACE和Sorfenib中联合羟基喜树碱加吡柔比星/表柔比星的联合疗法可作为一线治疗。</p></sec><sec id="s9"><title>5. 展望</title><p>随着科技的进步及分子生物学领域的发展，癌症已不再是让人闻风丧胆的恶疾，相信肝癌也是如此。实现肿瘤与机体和平共处，延长患者的生存时间，改善终末期患者的生活质量，减少疾病带来的痛苦，一直以来都是广大临床医师和患者所追求的目标。TACE联合索拉非尼可以延长患者的无进展时间，为进一步的治疗争取了时间，大家应当引起重视。</p></sec><sec id="s10"><title>文章引用</title><p>姚 欣,杨 建军. TACE联合索拉非尼治疗原发性肝癌的研究进展 Research Progress of TACE Combined with Sorafenib in the Treatment of HCC[J]. 亚洲肿瘤科病例研究, 2020, 09(04): 17-21. https://doi.org/10.12677/ACRPO.2020.94004</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38318-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">刘文东. 原发性肝癌诊疗进展[J]. 中西医结合心血管病电子杂志, 2018, 6(31): 162-163.</mixed-citation></ref><ref id="hanspub.38318-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">黄成, 孙惠川. 《原发性肝癌诊疗规范(2019年版)》肝脏外科领域更新的展望[J]. 外科理论与实践, 2020, 25(1): 6-9.</mixed-citation></ref><ref id="hanspub.38318-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Han, K. and Kim, J.H. (2015) Transarterial Chemoembolization in Hepatocellular Carcinoma Treatment: Barcelona Clinic Liver Cancer Staging System. World Journal of Gastroenterology, 21, 10327-10335.  
&lt;br&gt;https://doi.org/10.3748/wjg.v21.i36.10327</mixed-citation></ref><ref id="hanspub.38318-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chang, L., Wang, Y., Zhang, J., et al. (2017) The Best Strategy for HCC Patients at Each BCLC Stage: A Network Meta-Analysis of Observational Studies. Oncotarget, 8, 20418-20427. &lt;br&gt;https://doi.org/10.18632/oncotarget.14668</mixed-citation></ref><ref id="hanspub.38318-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">闫东. 2018《CSCO原发性肝癌诊疗指南》解读——肝动脉介入治疗部分[J]. 肝癌电子杂志, 2018, 5(3): 4-7.</mixed-citation></ref><ref id="hanspub.38318-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ogasawara, S., Ooka, Y., Koroki, K., et al. (2020) Switching to Systemic Therapy after Locoregional Treatment Failure: Definition and Best Timing. Clinical and Molecular Hepatology, 26, 155-162.  
&lt;br&gt;https://doi.org/10.3350/cmh.2019.0021n</mixed-citation></ref><ref id="hanspub.38318-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Li, L., Zhao, W., Wang, M., et al. (2018) Transarterial Chemoembo-lization plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review and Me-ta-Analysis. BMC Gastroenterology, 18, 138.  
&lt;br&gt;https://doi.org/10.1186/s12876-018-0849-0</mixed-citation></ref><ref id="hanspub.38318-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Raoul, J.L., Forner, A., Bolondi, L., Cheung, T.T., Kloeckner, R. and de Baere, T. (2019) Updated Use of TACE for Hepatocellular Carcinoma Treatment: How and When to Use It Based on Clinical Evidence. Cancer Treatment Reviews, 72, 28-36. &lt;br&gt;https://doi.org/10.1016/j.ctrv.2018.11.002</mixed-citation></ref><ref id="hanspub.38318-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lencioni, R., Petruzzi, P. and Crocetti, L. (2013) Chemoemboliza-tion of Hepatocellular Carcinoma. Seminars in Interventional Radiology, 30, 3-11. &lt;br&gt;https://doi.org/10.1055/s-0033-1333648</mixed-citation></ref><ref id="hanspub.38318-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">王瑞航, 姚升娟, 张晨, 等. 肝动脉化疗栓塞介入术对原发性肝癌患者近期疗效及Child-Pugh分级的影响[J]. 医学信息, 2020, 33(17): 101-102.</mixed-citation></ref><ref id="hanspub.38318-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, M., Xiang, P. and Jiang, H. (2018) TransArterial ChemoEmbolization (TACE) with Platinum versus Anthracyclines for Hepatocellular Carcinoma: A Meta-Analysis. International Journal of Surgery, 53, 151-158.  
&lt;br&gt;https://doi.org/10.1016/j.ijsu.2018.03.049</mixed-citation></ref><ref id="hanspub.38318-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Abdelgalil, A.A., Alkahtani, H.M. and Al-Jenoobi, F.I. (2019) So-rafenib. In: Profiles of Drug Substances, Excipients, and Related Methodology, Vol. 44, Elsevier, Amsterdam, 239-266. &lt;br&gt;https://doi.org/10.1016/bs.podrm.2018.11.003</mixed-citation></ref><ref id="hanspub.38318-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Leal, C.R.G., Magalhães, C., Barbosa, D., et al. (2018) Surviv-al and Tolerance to Sorafenib in Child-Pugh B Patients with Hepatocellular Carcinoma: A Prospective Study. Investiga-tional New Drugs, 36, 911-918.  
&lt;br&gt;https://doi.org/10.1007/s10637-018-0621-x</mixed-citation></ref><ref id="hanspub.38318-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ziogas, D.C., Papadatos-Pastos, D., Thillai, K., et al. (2017) Effi-cacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Age Is Not a Problem. European Journal of Gastroenterology &amp; Hepatology, 29, 48-55. &lt;br&gt;https://doi.org/10.1097/MEG.0000000000000739</mixed-citation></ref><ref id="hanspub.38318-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhuang, B.W., Li, W., Xie, X.H., et al. (2019) Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Systematic Review and Me-ta-Analysis. Japanese Journal of Clinical Oncology, 49, 845-855. &lt;br&gt;https://doi.org/10.1093/jjco/hyz069</mixed-citation></ref><ref id="hanspub.38318-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Wang, K., Wang, M., et al. (2017) Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Oncotarget, 8, 29416-29427. &lt;br&gt;https://doi.org/10.18632/oncotarget.15075</mixed-citation></ref><ref id="hanspub.38318-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, J., Yin, X., Tang, B., et al. (2019) Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International, 2019, Article ID: 2141859. &lt;br&gt;https://doi.org/10.1155/2019/2141859</mixed-citation></ref><ref id="hanspub.38318-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Y., Chen, B., Liu, N., et al. (2017) Overall Survival in Response to Sorafenib with Transarterial Chemoembolization for BCLC Stage B Hepatocellular Car-cinoma: Propensity Score Analysis. International Journal of Clinical Pharmacology and Therapeutics, 55, 498-508. &lt;br&gt;https://doi.org/10.5414/CP202787</mixed-citation></ref><ref id="hanspub.38318-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kok, V.C., Chen, Y.C., Chen, Y.Y., et al. (2019) Sorafenib with Transarte-rial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Na-tionwide Population-Based Cohort Study. Cancers (Basel), 11, 985. &lt;br&gt;https://doi.org/10.3390/cancers11070985</mixed-citation></ref><ref id="hanspub.38318-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Feng, F., Jiang, Q., Jia, H., et al. (2018) Which Is the Best Combi-nation of TACE and Sorafenib for Advanced Hepatocellular Carcinoma Treatment? A Systematic Review and Network Meta-Analysis. Pharmacological Research, 135, 89-101. &lt;br&gt;https://doi.org/10.1016/j.phrs.2018.06.021</mixed-citation></ref></ref-list></back></article>